Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a meningioma confirmed by pathology (tissue test) and concern for recurrence or leftover tumor on MRI
- Or you have another brain tumor known to have somatostatin receptor 2 (SSTR2) (the study may still enroll for feasibility)
- You can have MRI at your site—if you can’t do 3T, you may still do 1.5T MRI
- You can safely receive contrast dye used with MRI (gadolinium) and you have no known gadolinium contraindication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two similar PET scan medicines to see which one best helps identify meningiomas before surgery. If you’re getting pre-surgery testing, participating may help improve how doctors choose the best scan.
This trial uses a special PET scan (DOTATATE) to help plan radiation treatment for meningioma, a type of brain tumor. It aims to make radiation more precise, possibly reducing side effects.
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
This study tests how well a new PET/CT scan using 68Ga-DOTATATE can find neuroblastoma. It’s for children and young adults who are being planned for a different scan (123I-MIBG) to compare imaging results.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.